

TIL therapy - Pipeline Insight, 2021

<https://marketpublishers.com/r/T82FFC5F4789EN.html>

Date: October 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: T82FFC5F4789EN

Abstracts

This report can be delivered to the clients within 48-72 hours

DelveInsight's, "TIL therapy – Pipeline Insight, 2021," report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in TIL therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

TIL therapy Understanding

TIL therapy: Overview

TIL (tumor-infiltrating lymphocyte) therapy is a type of cellular immunotherapy that may be used to treat head and neck squamous cell carcinoma, melanoma, lung cancer, genitourinary cancers and a growing list of other malignancies. Cellular immunotherapy leverages components of the patient's own immune system to seek out and attack specific cancer cells. Because TILs come directly from the tumor, they already recognize many targets on the cancer cells. This makes them a very attractive therapy. Engineering TILs enhances their ability to fight the cancer cells. Currently, TIL therapies are only available through clinical trials. Currently, TIL therapy can be used to treat melanoma, variations of carcinoma, lung cancer, breast cancer, and genitourinary cancer.

'TIL therapy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the TIL therapy pipeline landscape is provided which includes the disease overview and TIL therapy treatment guidelines. The assessment part of the report embraces, in depth TIL therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, TIL therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence TIL therapy R&D. The therapies under development are focused on novel approaches to treat/improve TIL therapy.

TIL therapy Emerging Drugs Chapters

This segment of the TIL therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

TIL therapy Emerging Drugs

LN-145: Iovance Therapeutics

Autologous tumour infiltrating lymphocytes is derived through isolation of a patient's own naturally occurring TIL from a sample of cancerous tumor removed from the patient. The expanded and engineered TIL are then administered via intravenous infusion back to the patient as LN-145 (TIL therapy), with the intention that the TIL will target and infiltrate cancer in the patient and attack the cancer in greater number. It is currently being evaluated in Phase II clinical trial for the treatment of cervical cancer; colorectal cancer; Head and neck cancer; malignant melanoma; Non-small cell lung cancer.

ITIL-168: Instil Bio

ITIL-168 is an investigational, autologous cell therapy made from tumor infiltrating lymphocytes, or TILs. ITIL-168 is manufactured with Instil's proprietary, optimized, and scalable manufacturing process, which has been designed to capture and preserve the maximum diversity of each patient's TILs; the manufacturing process also offers significant scheduling flexibility for patients and physicians at the time of both tumor resection and TIL treatment. The therapy is being investigated in Phase II stage of development for the treatment of malignant melanoma.

Further product details are provided in the report.....

TIL therapy: Therapeutic Assessment

This segment of the report provides insights about the different TIL therapy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in TIL therapy

There are approx. 15+ key companies which are developing the therapies for TIL therapy. The companies which have their TIL therapy drug candidates in the most advanced stage, i.e. Phase II include, Iovance Therapeutics.

Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

TIL therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TIL therapy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TIL therapy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIL therapy drugs.

TIL therapy Report Insights

TIL therapy Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

TIL therapy Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing TIL therapy drugs?

How many TIL therapy drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TIL therapy?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TIL therapy therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for TIL therapy and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

- Introduction
- Executive Summary
- TIL therapy: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
 - Comparative Analysis
- Drug Name: Company Name
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report
- Mid Stage Products (Phase II)
 - Comparative Analysis
- LN-145: Iovance Therapeutics
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report
- Early stage products (Phase I)
 - Comparative Analysis
- TILT-123: TILT Biotherapeutics
 - Product Description
 - Research and Development
 - Product Development Activities

Drug profiles in the detailed report
Inactive Products
 Comparative Analysis
TIL therapy Key Companies
TIL therapy Key Products
TIL therapy- Unmet Needs
TIL therapy- Market Drivers and Barriers
TIL therapy- Future Perspectives and Conclusion
TIL therapy Analyst Views
TIL therapy Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for TIL therapy

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for TIL therapy

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: TIL therapy - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/T82FFC5F4789EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T82FFC5F4789EN.html>